In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Myriad Genetics Inc.

www.myriad.com

Latest From Myriad Genetics Inc.

Myriad, Merck, And AstraZeneca Expand Collab On BRACAnalysis For Prostate Cancer Test

Myriad, Merck & Astra Zeneca are expanding their partnership to develop the BRACAnalysis CDx prostate cancer test.

Diagnostics Commercial

Results Recap: Support For Medtronic's 'Suspend Before Low' Insulin Pump Feature; Neuroelectrics' Starstim Treats Epilepsy Seizures

Medtech Insight's Results Recap covers major device trial results appearing on MedDeviceTracker. This week's edition, covering Feb. 22 through Feb. 28, includes published results from trials of Medtronic’s closed-loop artificial pancreas, Neuroelectrics’ nerve stimulation device to treat seizures, and Myriad’s companion diagnostic for pancreatic cancer.

Tracking Trials Research & Development

Breast Surgeons Advise All Breast Cancer Patients Be Offered Genetic Testing

The American Society of Breast Surgeons published new guidelines, recommending that genetic testing should be made available to all patients with a history of breast cancer. The new recommendations are not in line with existing guidelines made by the National Comprehensive Cancer Network.

Cancer In Vitro Diagnostics

Myriad Finishes Big Year With NICE Endorsement Of EndoPredict Breast Cancer Diagnostic

The UK's National Institute for Health and Care Excellence (NICE) has included Myriad Genetics' EndoPredict in its recommendations for guiding adjuvant chemotherapy decisions for certain early breast cancer patients. The recommendation comes just a few weeks after new data showing the long-term prognostic value of the EndoPredict test was presented at the San Antonio Breast Cancer Symposium. The company is also making progress on its Vectra rheumatoid arthritis prognostic system with the publication of a large commercial cohort and several clinical studies on development of the adjusted Vectra score.

Clinical Trials In Vitro Diagnostics
See All

Company Information

  • Industry
  • Biotechnology
    • Pharmacogenetics-Pharmacogenomics
  • In Vitro Diagnostics
    • Molecular Diagnostics & Genetic Testing
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Dermatology
  • Gynecological, Urological
  • Immune Disorders
  • Infectious & Viral Diseases
  • Neurology, Nervous System
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Myriad Genetics Inc.
  • Senior Management
  • Mark C Capone, Pres. & CEO
    R. Bryan Riggsbee, CFO
    Jerry H Lanchbury, PhD, CSO
    Johnathan M Lancaster, MD, PhD, CMO
    Rishi Kacker, CTO
  • Contact Info
  • Myriad Genetics Inc.
    Phone: (801) 584-3600
    320 Wakara Way
    Salt Lake City, UT 84108
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register